In focus · trending topic

OTIVIDEX

19 stories · following the connections

Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update

By Nasdaq OMXNov 1, 2017, 8:06 PM UTC

Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease

By Nasdaq OMXAug 30, 2017, 11:00 AM UTC

Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

By Nasdaq OMXAug 3, 2017, 8:12 PM UTC

Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update

By Nasdaq OMXJul 27, 2017, 11:30 AM UTC

Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa

By Nasdaq OMXJul 18, 2017, 11:30 AM UTC

Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes

By Nasdaq OMXJun 22, 2017, 11:30 AM UTC

Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease

By Nasdaq OMXJun 20, 2017, 11:30 AM UTC

Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference

By Nasdaq OMXMay 10, 2017, 8:07 PM UTC